The strategic acquisition provides Roche access to Carmot’s portfolio, which notably includes three lead molecules, all GLP-1 analogues, currently in the advanced stages of clinical trials for obesity and type 2 diabetes. It also positions the company on par with other industry leaders in the realm of GLP-1 analogues, such as Novo Nordisk, Eli Lilly and others.
Tag Archive for: Eli Lilly
The multimillion-dollar collaboration will develop small molecule drugs against undisclosed targets.
The company launched a website to help people with obesity get prescriptions through telehealth providers and provide home delivery of its weight-loss medicines.
Eli Lilly and Company announced the successful completion of its acquisition of POINT Biopharma Global Inc., a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
Bristol Myers Squibb said on Tuesday it would buy RayzeBio for about $4.1 billion to bolster its cancer drug business, marking the second multi-billion dollar deal struck by the drugmaker in less than a week.
Sweden’s drugs agency on Monday asked doctors to hold off on prescribing diabetes drugs for the treatment of obesity, pointing to signs that a spike in such usage has left diabetics short of medication.
Several big-name drugmakers are weighing in on the opportunity in the weight-loss drugs market.
Eli Lilly’s recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost customers whose health insurance does not cover the drug $550 a month, or half the list price, the company announced today.
Tema ETFs has launched a new exchange traded fund that tracks popular drugmakers like Novo Nordisk and Eli Lilly, aiming to tap into growing demand for their weight-loss and diabetes drugs.
Successful drugs from Novo Nordisk and Eli Lilly are just the beginning of what one analyst says could be “the largest therapeutic class of drugs that the biopharma industry has ever seen.”
